NCT06845306

Brief Summary

Anastomotic leakage (AL) is a serious complication after surgery for colon cancer, leading to a significant increase in mortality.Intraoperative fluorescence imaging using indocyanine green has proven to be a feasible and reproducible technique for real-time perfusion assessment. An increasing number of studies are being published on the use of indocyanine green (ICG) fluorescence imaging in colorectal cancer surgery, showing promising results. Therefore, we propose conducting a multicenter, randomized controlled trial to investigate the potential use of quantitative assessment of near-infrared fluorescence imaging with indocyanine green (ICG) to prevent anastomotic leaks during colorectal surgery.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,268

participants targeted

Target at P75+ for phase_3 colorectal-cancer

Timeline
4mo left

Started Jun 2025

Shorter than P25 for phase_3 colorectal-cancer

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress75%
Jun 2025Sep 2026

First Submitted

Initial submission to the registry

February 20, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 25, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

June 1, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

February 25, 2025

Status Verified

January 1, 2025

Enrollment Period

1.1 years

First QC Date

February 20, 2025

Last Update Submit

February 24, 2025

Conditions

Keywords

ICG-guided quantitative assessment of bowel perfusion

Outcome Measures

Primary Outcomes (1)

  • 30-days Anastomotic Leakage (AL) rate

    Anastomotic leakage rate

    30-days

Secondary Outcomes (3)

  • complication rate

    30-days

  • mortality

    30-days

  • days in hospital stay

    90-days

Study Arms (2)

The ICG group

ACTIVE COMPARATOR

The ICG group, where, before creating the anastomosis, intestinal blood flow will be assessed using quantitative near-infrared fluorescence imaging using indocyanine green.

Drug: ICG-guided bowel perfusion assessment

The control group

PLACEBO COMPARATOR

The control group, where before the creation of the anastomosis, the intestinal blood flow will not be assessed.

Other: Conventional Bowel Anastomosis group

Interventions

ICG will be injected before anastomosis is created, to quantitatively assess the perfusion status of the bowel.

The ICG group

conventional perfusion assessment

The control group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged over 18 years old
  • ECOG status 0-2
  • Written informed consent
  • histologically confirmed neoplasms malignant of the colon (caecum, ascending, transverse, descending, sigmoid)
  • Scheduled for colorectal resection with primary anastomosis

You may not qualify if:

  • Pregnancy or breast feeding
  • Colon obstruction, perforation or bleeding complicating the tumor
  • Medical contraindications for surgical treatment
  • Known allergy or history of adverse reaction to ICG, iodine or iodine dyes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

BELOOSTROV Clinic of High Technologies

Vsevolozhsk District, Leningradskaya Oblast', 188640, Russia

Location

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Study Officials

  • Victor Kashchenko, Doctor of Medical Sciences

    BELOOSTROV Clinic of High Technologies

    STUDY DIRECTOR

Central Study Contacts

Vadim Kuznetsov

CONTACT

Timur Lankov

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Intraoperative imaging cannot blind the surgeon. The patient is only blinded prior to surgery.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: multicentre randomized controlled trial
Sponsor Type
NETWORK
Responsible Party
SPONSOR INVESTIGATOR
PI Title
The doctor is a researcher

Study Record Dates

First Submitted

February 20, 2025

First Posted

February 25, 2025

Study Start

June 1, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

February 25, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, ICF

Locations